0001916048-26-000009.txt : 20260723 0001916048-26-000009.hdr.sgml : 20260723 20260723183924 ACCESSION NUMBER: 0001916048-26-000009 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20260721 FILED AS OF DATE: 20260723 DATE AS OF CHANGE: 20260723 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Warren Eric CENTRAL INDEX KEY: 0001916048 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-41614 FILM NUMBER: 261198117 MAIL ADDRESS: STREET 1: 3891 RANCHERO DRIVE STREET 2: SUITE 150 CITY: ANN ARBOR STATE: MI ZIP: 48108 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Mineralys Therapeutics, Inc. CENTRAL INDEX KEY: 0001933414 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 150 N. RADNOR CHESTER RD. STREET 2: SUITE F200 CITY: RADNOR STATE: PA ZIP: 19087 BUSINESS PHONE: (888) 378-6240 MAIL ADDRESS: STREET 1: 150 N. RADNOR CHESTER RD. STREET 2: SUITE F200 CITY: RADNOR STATE: PA ZIP: 19087 4 1 wk-form4_1784846362.xml FORM 4 X0609 4 2026-07-21 0 0001933414 Mineralys Therapeutics, Inc. MLYS 0001916048 Warren Eric false 150 N. RADNOR CHESTER ROAD SUITE F200 RADNOR PA 19087 0 1 0 0 Chief Commercial Officer 1 Common Stock 2026-07-21 4 M 0 7438 13.24 A 45838 D Common Stock 2026-07-21 4 S 0 7438 26.8735 D 38400 D Stock Option 13.24 2026-07-21 4 M 0 7438 0 D 2035-04-21 Common Stock 7438 245438 D These transactions were effected pursuant to a Rule 10b5-1 stock selling plan adopted on March 27, 2026. The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $26.53 to $27.09. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4. The stock option vested as to 25% of the underlying shares on the first anniversary of the grant date, with the remaining shares vesting in 36 substantially equal monthly installments thereafter. /s/ Adam Levy, Attorney-in-fact 2026-07-23